Get the latest news, insights, and market updates on SLP (Simulations Plus, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Simulations Plus Reports First Quarter Fiscal 2026 Financial Results
RESEARCH TRIANGLE PARK, N.C., January 08, 2026--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its first quarter fiscal 2026, ended November 30, 2025. Jan 8, 2026 - $SLP
Simulations Plus: Fiscal Q1 Earnings Snapshot
RESEARCH TRIANGLE PARK, N.C. (AP) — Simulations Plus Inc. SLP) on Thursday reported earnings of $676,000 in its fiscal first quarter. The Research Triangle Park, North Carolina-based company said it had profit of 3 cents per share. Jan 8, 2026 - $SLP
Best Stock Trade of 2025 Keeps Running, Question Is for How Long
Memory and storage companies were the leading performers in the S&P 500 Index last year, as the massive amounts of cash being spent on building out AI infrastructure trickled down to some traditionally staid parts of the tech sector. Sandisk popped 16% on the first trading day of the year and then soared 28% on Tuesday after Nvidia Corp. Chief Executive Officer Jensen Huang highlighted the need for more memory and storage in the AI ecosystem. Meanwhile, Western Digital, Seagate and Micron have all posted double-digit percentage gains to start 2026, although all three stocks fell on Wednesday. Jan 8, 2026 - $SLP
Simulations Plus (SLP) Highlights FDA Alignment as Citizens Maintains Market Perform
Simulations Plus, Inc. (NASDAQ:SLP) is one of the best healthcare AI stocks to buy now. On December 9, Simulations Plus, Inc. (NASDAQ:SLP) issued a press release highlighting how its technologies align with the FDA’s new regulatory direction. On December 2, the FDA released a draft guidance focused on streamlined nonclinical safety studies for monospecific monoclonal […] Dec 22, 2025 - $SLP
Simulations Plus Announces First Quarter Fiscal Year 2026 Earnings and Conference Call Date
RESEARCH TRIANGLE PARK, N.C., December 17, 2025--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus", "SLP"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will report first quarter fiscal 2026 financial results after the market close on Thursday, January 8, 2026. Dec 17, 2025 - $SLP
Simulations Plus Positioned to Capitalize on FDA’s Streamlined Nonclinical Safety Guidance with Advanced Mechanistic and Model-Informed Solutions
RESEARCH TRIANGLE PARK, N.C., December 09, 2025--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today responded to the U.S. Food and Drug Administration’s draft guidance on streamlined nonclinical safety studies for monospecific monoclonal antibodies. The guidance encourages reduced reliance on animal studies and elevates mechanistic understanding, pharmacokineti Dec 9, 2025 - $SLP
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple